Who founded Nanograb?

Nanograb was founded by Debesh Mandal, Christopher Lau, Shanil Panara in 2023.

Who are Nanograb's investors?

Nanograb's investors include Recode Ventures, Sterling Road, Y Combinator, Agrolimen Ventures, BlueYard Capital, Sandhill (ex Stonks).

Where is Nanograb headquartered?

Nanograb is headquartered in San Francisco, US.

Nanograb

YC S23

San Francisco, US · Founded 2023 · 5 employees · 6 known investors

Find your way into Nanograb

Paths you didn't know you had: your email and LinkedIn already hold routes to the Nanograb team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.

Biotech Healthtech AI-powered Drug Discovery Nanomedicine Drug Delivery TherapeuticsUnited KingdomEurope

Founders & leadership· Y Combinator alumni (S23)

Nanograb was founded in 2023 by Debesh Mandal, Christopher Lau, and Shanil Panara.

Debesh Mandal Co-Founder and CEODebesh Mandal holds a PhD in Computational Biophysics from Imperial College London and has experience in molecular simulations and scientific software development. He previously worked as a software engineer at Fabricnano and is now co-founder and CEO of Nanograb.

Christopher Lau Co-FounderChristopher Lau holds an M.Eng in Biomaterials and Tissue Engineering from Imperial College London and has worked on biosensor development using aptamers and a drug delivery device for hypertension management.

Shanil Panara Co-FounderShanil Panara is a cofounder and computational lead at Nanograb, with doctoral study in physics at Imperial College London. His expertise spans computational methods and physics applications.

Stefano Angioletti-Uberti

Investors · 6

Recode Ventureslisted by Recode VenturesSan Franciscovia Armen Vidian · inferred

How we know: Recode Ventures's portfolio page · Y Combinator's founder network · Not right? Tell us

Sterling Roadlisted by Sterling RoadSan Francisco · $25K – $150K

How we know: Sterling Road's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Agrolimen Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

BlueYard CapitalreportedBerlin · $500K – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Sandhill (ex Stonks)reportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 5

Sixfold BioscienceSixfold develops RNA delivery technology for the biotech industry. The company was founded by an oncologist and plant scientist and focuses on advancing RNA-based therapeutic approaches through proprietary delivery methods.

Rejuvenation Technologies Inc.Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.

Nuntius TherapeuticsNuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.

KeylikaKeylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

ConvexiaConvexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.

Companies working in the same space as Nanograb.

Legal entities · 2

corporate structure

Nanograb Inc.

Nanograb Limited

In the news

🧪 Nanograb - Multivalent nanoparticles for next-generation targeted drugsycombinator.com · Jul 2023

Nanograb Funding | Complete Analysis | Extruct AIextruct.ai

Frequently asked questions

What does Nanograb do?: Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
Who founded Nanograb?: Nanograb was founded by Debesh Mandal, Christopher Lau, Shanil Panara in 2023.
Who are Nanograb's investors?: Nanograb's investors include Recode Ventures, Sterling Road, Y Combinator, Agrolimen Ventures, BlueYard Capital, Sandhill (ex Stonks).
Where is Nanograb headquartered?: Nanograb is headquartered in San Francisco, US.